Literature DB >> 2877885

Interaction of bisoprolol with cimetidine and rifampicin.

W Kirch, I Rose, I Klingmann, J Pabst, E E Ohnhaus.   

Abstract

In 6 healthy volunteers the pharmacokinetics of bisoprolol under steady-state conditions was investigated over three consecutive phases: over 7 days of 10 mg of bisoprolol once daily per os, 7 days of 10 mg of bisoprolol once daily plus 400 mg of cimetidine t.i.d. and 14 days of 10 mg of bisoprolol and 600 mg of rifampicin once daily with adequate intervals free of medication. After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h. Cimetidine did not cause any significant changes in the pharmacokinetics of bisoprolol. Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h). Accordingly, total body clearance increased to 23.8 +/- 2.5 l/h (p less than 0.05). In conclusion bisoprolol showed a statistically significant but probably clinically not important interaction with the enzyme-inducing drug rifampicin, but not with the enzyme inhibitor cimetidine.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877885     DOI: 10.1007/bf00870987

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Dose-response relationship of the beta-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis.

Authors:  P Dorow; U Tönnesmann
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  Interaction of cimetidine with metoprolol, propranolol, or atenolol.

Authors:  W Kirch; H Köhler; H Spahn; E Mutschler
Journal:  Lancet       Date:  1981-09-05       Impact factor: 79.321

3.  The interaction of cimetidine with metoprolol, atenolol, propranolol, pindolol and penbutolol.

Authors:  H Spahn; W Kirch; E Mutschler
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

4.  A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine.

Authors:  B K Park
Journal:  J Steroid Biochem       Date:  1978-10       Impact factor: 4.292

5.  Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine.

Authors:  W Kirch; H Spahn; H Köhler; E E Ohnhaus; E Mutschler
Journal:  Klin Wochenschr       Date:  1982-11-15

6.  Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs.

Authors:  H J Schliep; J Harting
Journal:  J Cardiovasc Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.105

7.  Metabolism of pindolol in patients with renal failure.

Authors:  E E Ohnhaus; H Heidemann; J Meier; G Maurer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Effect of rifampicin on metoprolol and antipyrine kinetics.

Authors:  P N Bennett; V A John; V B Whitmarsh
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

9.  Reduction of liver blood flow and propranolol metabolism by cimetidine.

Authors:  J Feely; G R Wilkinson; A J Wood
Journal:  N Engl J Med       Date:  1981-03-19       Impact factor: 91.245

10.  Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist.

Authors:  G Leopold; W Ungethüm; J Pabst; Z Simane; K U Bühring; H Wiemann
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

  10 in total
  13 in total

Review 1.  Bisoprolol: a review of its use in chronic heart failure.

Authors:  Jane K McGavin; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

Authors:  S G Lancaster; E M Sorkin
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 4.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Interaction of cimetidine with bisoprolol.

Authors:  A Somogyi; M Muirhead
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Population pharmacokinetics of bisoprolol in patients with chronic heart failure.

Authors:  Valentina N Nikolic; Tatjana Jevtovic-Stoimenov; Radmila Velickovic-Radovanović; Stevan Ilic; Marina Deljanin-Ilic; Dragan Marinkovic; Svetlana Apostolović; Dragana Stanojevic; Slavoljub Zivanovic; Nikola Stefanovic; Srdjan Pesic; Dejana Ruzic Zecevic; Jasmina R Milovanovic; Slobodan M Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2012-10-24       Impact factor: 2.953

7.  Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

Authors:  P A Soons; C Grib; D D Breimer; W Kirch
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

Review 8.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.

Authors:  W Kirch; I Rose; H G Demers; G Leopold; J Pabst; E E Ohnhaus
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

10.  Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity.

Authors:  W Kirch; S Milferstädt; A Halabi; I Rocher; C Efthymiopoulos; L Jung
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.